Teva pharmaceuticals inched closer to junk on Thursday after Moody's placed its rating on review for downgrade, saying new cost cuts - including slashing 14,000 jobs - were not enough. After initially tightening on news of the corporate restructuring, Teva bonds turned sharply wider following the Moody's announcement, more than erasing the day's prior gains.
展开▼
